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Tumor Cell Intravasation Minireview
Alu-cidated: The Chick
Embryo Opens the Window
level, it is a dramatic breach of the normal situation of
organizational stability of tissues. However, it should be
noted that vascular dissemination is utilized to a limited
extent during normal embryogenesis for the correct po-
sitioning of cells arising in one location and whose final
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University of California location is in a distant tissue. Vascular transport of the
Davis, California 95616-8535 primordial germ cells, arguably the most important cell
type of the body, is a dramatic example of this process
in the developing embryo. In the adult, lymphocytes andIn the normal situation, the organization of the tissues
leucocytes intravasate from their tissues of origin toand organs is stable for the life of the organism. The
circulate in the blood and then extravasate at sites ofdissemination of cells from a primary tumor by invasion
inflammation. Thus, a full understanding of the mecha-and metastasis represents the best-known situation
nisms of tissue metastasis is both of major fundamentalwhere the normal restraints stabilizing cellular position-
and applied interest.ing in the tissues are in abeyance (Armstrong, 1984).
What are the cellular and molecular processes utilizedInvasion is the intrusion of cells of one tissue type into
by the tumor to establish colonies in distant tissues?the fabric of contiguous tissues and is responsible for
Interestingly, we now know a great deal about the firstthe local dissemination of neoplastic tissue. Metastasis
step of metastasis, tumor angiogenesis (Hanahan andis the dissemination of tumor cells to organs distant
from the parent tumor and involves the transport of
single cells or small clusters of neoplastic cells through
the fluid spaces of the body. The avenues for metastasis
include the cerebrospinal fluid, the peritoneal fluid, the
lymph, and the blood. The most frequent route for tumor
metastasis utilizes the vasculature, and vascular metas-
tasis has received the most study from experimentalists.
As the hallmark of tumor malignancy, the processes
responsible for tumor dissemination have come under
increasing scrutiny in recent years. Metastasis of solid
tumors is a complicated multistep cascade that is initi-
ated in most cases by the invasion of the tumor by
capillaries from the surrounding host tissues. Tumor
vascularization clearly is one of the rate-limiting steps
for tumor growth and metastasis, because unvascu-
larized primary tumors typically are maintained as small
dormant nodules of tissue whose volume is kept con-
stant by a balance of cell proliferation and cell death,
and whose cells are confined within the boundary of the
parent tumor (Holmgren et al., 1995). The next step in
metastasis requires that the tumor cells intravasate into
the vascular spaces to establish direct contact with the
blood. During intravasation, the tumor cells invade
across the endothelial basal lamina and migrate be-
tween the endothelial cells lining the capillaries that ser-
vice the tumor (Figure 1). The intravasated tumor is then
free to release neoplastic cells into the blood for their
systemic dispersal to all tissues of the body. Success
in metastasis requires that these tumor emboli survive
the stage of vascular transport and that they arrest in
the capillary beds of distant organs and engage in a Figure 1. Intravasation and Other Steps in the Metastatic Cascade
second round of invasion, extravasation, whereby neo- Examined in the Report by Kim et al. (1998)
plastic cells exit from the vessel lumen into the sur- The stage is set for intravasation by the placement of tumor cells
rounding stromal tissue. The colonizing tumor cells must onto the surface of the chorionic epithelium and their invasion into
the mesenchymal stroma of the chorioallantois. There the tumorthen replicate in this new environment to grow from
cells encounter a luxuriant microvasculature that is the target formicrometastases into the progressively enlarging tu-
intravasation, which is the invasion of tumor cells across the endo-mors that will threaten the survival of the host.
thelium to establish direct contact with the blood. Metastasis resultsThe situation of tumor metastasis is clearly a patho-
from release of tumor cells from the intravasated tissue and their
logical process. Clinically, it produces numbers of sec- transport to distant organs,where the tumor cells arrest andextrava-
ondary tumors that remain even after the surgeon's scal- sate. Tumor cells that have metastasized to distant sites of the
chorioallantois are the indicators of intravasation.pel has disposed of the primary tumor. At a more basic
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Folkman, 1996; Zetter, 1998), and are seeing the suc- A clever trick used by Kim et al. (1998) for the detection
of very small numbers of intravasated tumor cells in thecessful dissection of the last steps, lodgement, extrava-
sation, and secondary growth (Chambers and Matrisian, organs of assay was the quantitation of Alu sequences,
present in high abundance in the DNA of the explanted1997), but until the appearance of a paper from Kim et
al. (1998 [this issue of Cell]), we knew essentially nothing human tumor cells but absent from the host chicken
cells. The Alu sequences, unique to human and higherabout the important step of tumor cell intravasation. In
order to accomplish intravasation, the tumor cell must primate DNA, are repetitive sequences approximately
300 bp long and flanked at each end by highly conservedtraverse the subendothelial basal lamina and move
across or eliminate the single-cell layer of endothelial 25 bp and 16 bp regions. Sense and antisense primers
designed from these regions enabled the conservedcells that separates tumor tissue from the blood. One
of the interesting findings of this report is the demonstra- ends to be used for PCR amplification of human Alu
DNA ina background of chicken DNA. PCR amplificationtion of essential roles for matrix metalloproteases (MMPs)
and for the urokinase plasminogen activator receptor yielded a 220 bp radiolabeled band whose intensity was
proportional to the amount of human DNA present with(uPAR), and, by implication, for urokinase plasminogen
activator (uPA). a large excessof chickenDNA. Chicken DNA alone failed
to yield a PCR product, and as little DNA as from 50Our understanding of the molecular and cellular
mechanisms of metastasis has depended on the exploi- human cells added to the chick tissue yielded a detect-
able 220 bp signal. The detection trap for intravasationtation of model systems that isolate one or another of
the individual steps of this complicated, multistep pro- was set.
Kim et al. (1998) assayed intravasation by the appear-cess. In this context, the use by Kim et al. (1998) of the
chick chorioallantois for the characterization of tumor ance of human tumor cells in tissues distant from the
site of inoculation and connected to that location onlyintravasation was inspired. This is an in vivo model that
is facile, inexpensive, experimentally manipulable, and by the vascular and lymphatic systems. The logic was
that tumor cells found at these distant sites must havethat readily accepts and supports xenogenic trans-
plants. It is just such a xenogenic difference between reached them by vascular or lymphatic transport, and
for transport to have occurred, the tumor cells had tohost (chicken) and tumor (human) that Kim et al. (1998)
exploited for the detection and quantitation of the intra- have successfully intravasated into the blood or lymph.
The path taken by tumor cells that have intravasatedvasated tumor cells (see below). In the chorioallantois
grafting system, the chorioallantois is exposed by cut- into chorioallantoic capillaries is to the chorioallantoic
veins, then to the allantoic vein, which discharges intoting a window in the egg shell and tumor cells are then
explanted onto a suitably traumatized chorionic epithe- the posterior chamber of the heart. The cardiac blood,
with its cargo of intravasated tumor cells, then is distrib-lium (Armstrong et al., 1982). The explanted cells invade
across the damaged epithelium and into the mesenchy- uted to the body, with a major portion flowing directly
via the allantoic arteries back to the chorioallantois. Itmal connective tissue beneath, where they find a dense
bed of blood vessels that is the target for intravasation. is vascular-borne tumor cells delivered by this pathway
and captured by the capillary bed of regions of the cho-The chorioallantois is an extraembryonic organ formed
at day 4±5 of development (E4±E5) by the fusion of the rioallantois distant from the graft that were assayed by
Kim et al. (1998) (Figure 1). A second site for metastaticallantois and the chorion. It has a bilayered chorionic
epithelium positioned immediately beneath the egg arrest was found to be the embryonic liver.
When highly malignant, human epidermoid carcinomashell, a mesenchymal bed composed of mesoderm from
chorion and allantois, and an inner allantoic epithelium cells (HEp-3) were inoculated onto the patch of chorioal-
lantois exposed by the shell window (designated thethat encloses the allantoic cavity. During the next 7±8
days of development, the chorioallantois expands be- ªupper half chorioallantoisº), a significant level of human
220 bp PCR product was detected 30±50 hr later inneath the egg shell, eventually to envelop the entire
embryo. Between E7 and the stage of pipping at E20, the chorioallantois directly opposite the inoculation site
(designated the ªlower half chorioallantoisº). Kim et al.the chorioallantois serves as the respiratory organ of
the embryo. The chorioallantoic vasculature is contrib- (1998) demonstrated that the PCR signal measures DNA
from live tumor cells and not DNA from cellular debris,uted by the allantoic mesoderm and vascularizes the
mesenchyme and, in addition, establishes a dense capil- that its appearance is dose dependent on the tumor cell
inoculum, and that the tumor cells are not entering thelary plexus by E10-E12 that intrudes directly into the
chorionic epithelium. The endothelium shows rapid cell vasculature passively or incidently at inoculation but,
instead, mustcomplete active intravasation into the hostproliferation from E4 to E11, after which the rate of prolif-
eration experiences a rapid decline. It is at this stage embryo vasculature. The intravasation process, thus, is
active, progressive, and is initiated at a defined timethat the chorioallantois completes its growth and the
ectodermal capillary plexus becomes established. The period (30±50 hr postinoculation). Importantly, the intra-
vasation processappears tobe specific and selective. Incapillaries during the growth stage show a thin and in-
complete basal lamina and focal contact junctions be- addition to HEp-3, MDA-231, a highly malignant breast
carcinoma cell line, intravasates, while MCF-7, a nonag-tween endothelial cells that prevent transendothelial
passage of molecules larger than z20 kDa. Since large gressive breast tumor cell line does not. PC-3, a highly
malignant prostate tumor cell enters the chorioallantoicareas of the capillary endothelium are devoid of a basal
lamina, it is presumed that the interstitial matrix and vasculature, while LNCaP, a weakly malignant prostate
tumor cell, does not. Other malignant and nonmalignantthe adhesive junctions of the endothelium represent the
major barriers to intravasation of tumor cells. pairs of cell lines yielded similar differential results. At
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the stages of initial detection of tumor cells in the ventral Of the major MMPs, MMP-9 has in the past suffered
from some neglect, existing in the shadow of MMP-2,half chorioallantois, the inoculum had yet to form itself
into a definitive tumor and appears not yet to have ac- its close structural and functional homolog. An involve-
ment of MMP-9 in a variety of normal and pathologicaltively elicited a vascular supply, indicating that differ-
ences in angiogenesis of the different cell lines cannot conditions has recently begun to emerge, however.
Werb and colleagues (Vu et al., 1998) demonstrated thatunderlie the observed differences in intravasation. It ap-
pears that the malignant cells utilized the preexisting the MMP-9 gene knockout mouse exhibits a transient
enlargement in the osteogenic growth plate that corre-chorioallantoic vasculature for intravasation. Further-
more, since cells of all cell lines delivered to the blood lates with reduced angiogenesis of hypertrophic carti-
lage. This defect can be corrected by bone marrowby direct intravascular injection arrested in the capillary
bed of the chorioallantois with equal efficiency, differ- transplants from wild-type mice. Muschel and cowork-
ers (Bernard et al., 1994; Hua and Muschel, 1996)ences in arrest could not account for these observa-
tions. Recent reports indicate that extravasation of cells showed both by transfection of MMP-9 cDNA and by
transfection with specific antisense-RNA-ribozyme con-arrested in the chorioallantoic vasculature shows no
selectivity for tumor cells, with nonneoplastic cells ex- structs that enhanced expression of MMP-9 in nonmeta-
static cells activated a metastatic phenotype, and selec-travasating as efficiently as tumor cells (Koop et al.,
1996). Thus, Kim et al. (1998) appear to have been suc- tive loss of MMP-9 mRNA results in cells that retain
tumorigenicity but are no longer metastatic. Consistentcessful in isolating intravasation as the rate-limiting and
selective step in their assay. with the link by Kim et al. (1998) of intravasation to both
MMP-9 and the uPA/uPAR system, recent studies byWith intravasation defined and quantifiable in the
model, Kim et al. (1998) examined the enzymic require- Mazzieri et al. (1997) and Ramos-De Simone et al. (1998)
have shown that activation of pro-MMP-9 is accom-ments of the process. An involvement of uPA and its
cell surface receptor, uPAR had already been docu- plished by a uPA/plasmin/MMP proteolytic cascade.
The requirement both for MMP-9 and for uPA for intrava-mented for various facets of invasion and metastasis
(Ossowski, 1988; Kook et al., 1994), so for the present sation may reflect just this sort of complex proteolytic
activation cycle. The principal targets of the MMPs arestudy, their role in intravasation was examined directly.
Modified sublines of HEp-3 cells, in which surface uPAR proteins of the extracellular matrix, suggesting an in-
volvement in remodeling the stromal matrix of the cho-was reduced by 50%±70% through transfection of a
vector expressing antisense RNA for uPAR, exhibited rioallantois to enable the grafted tumor cells to contact
the endothelium.The uPA/plasmin system ismore broadlydramatically reduced intravasation compared to paren-
tal HEp-3 or cells transfected with the vector alone. This targeted and might play a dual role in intravasation:
the activation of MMP zymogens and the facilitation ofimplicates the uPA/uPAR cell surface proteolytic system
in the intravasation process. MMPs were also examined invasion across the endothelium itself and/or promotion
of the release of tumor cells into the blood after intrava-using substrate zymography to examine representative
MMPs of all eight of the intravasating and nonintravasat- sation has been accomplished.
A key to the success of the pioneering investigationing cell lines. MMP-1 (interstitial collagenase), MMP-2
(gelatinase A), and MMP-9 (gelatinase B) were produced by Kim et al. (1998) of the intravasation step of tumor
metastasis was the choice of the chicken chorioallantoisto varying levels by all of the cell lines. MMP-9 was
the only one of the three MMPs that was consistently as the host tissue. The chorioallanotis has long been a
favored system for the study of tumor angiogenesis andpresent in the intravasating cell types and absent or
barely detectable in the nonintravasating cells. Further, as a system for investigating metastasis of human tumor
cells. In addition to its several key advantages for thethe general MMP inhibitor, Marimastat, produced a 90%
reduction of intravasation, indicating that MMPs are present study, it has the additional advantage of favor-
able optical clarity for intravitalmicroscopy. This methodnecessary for this process. The absence of any toxic
effect by Marimastat and the documented specificity of allows the continuous microscopic observation of cells
within the vasculature of the living chorioallantois andthis class of inhibitors strongly implicates MMP proteo-
lytic function in the process of intravasation. The pur- has proven informative for the study of extravasation of
injected tumor cells arrested in the microvasculatureported involvement specifically of MMP-9 in intravasa-
tion, however, is not as compelling, because it is based (Koop et al., 1996). In the present context, it will be
on circumstantial evidence (i.e., tumor cells that intrava- informative to compare the detailed behavior of grafted
sate secrete MMP-9, while those that do not fail to ex- cells of the different intravasating and nonintravasating
press significant quantities of the enzyme). Many mem- cell lines and the behavior of control and Marimistat-
bers of the MMP family are not detectable by gelatin treated HEp-3 cells during the process of intravasation
zymography, and one or another of these undetected itself by direct microscopic study of the living tissues.
MMPs might be an active agent in intravasation and Of the different systems available for the study of metas-
would, of course, be inactivated by Marimistat. More tasis, arguably the chick chorioallanotis is the most ver-
direct studies of a role for MMP-9 could include activat- satile and, for the study of intravasation, is the premier
ing intravasation-incompetent tumor cell lines by trans- choice.
fection with cDNA for MMP-9, and eliminating MMP-9
from intravasation-competent cell lines with antisense Selected Reading
cDNA for the MMP-9 gene, or by coinoculation of intra-
vasation-competent cells with neutralizing anti-MMP-9 Armstrong, P.B. (1984). In Invasion, M. Mareel and K. Calman, eds.
(Oxford: Oxford University Press), pp. 126±167.antibodies.
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